# RA Capital Management

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/ra-capital-management
Canonical HTML page: https://getyourbrief.com/entity/ra-capital-management

## Timeline

- **2029**: Cash runway into first half of 2029 — Proceeds from the $150 million private placement are expected to fund a planned NDA submission and operations into the first half of 2029.
- **2028**: CRPS-RISE Phase 3 topline results expected — Ambros expects to report topline results from the pivotal CRPS-RISE trial evaluating neridronate in warm CRPS-1.
- **2026-08-21**: Merger and $150M financing announced — Werewolf Therapeutics and Ambros Therapeutics announce a definitive all-stock merger and an oversubscribed $150 million private placement.

## Recent coverage (2 stories, network-wide)

### Neridronate Phase 3 Backed by $150M Merger and Financing
2026-08-22 01:36:06 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Neridronate, an investigational CRPS-1 bisphosphonate already approved in Italy, moves into a 270-patient pivotal CRPS-RISE Phase 3 with FDA Breakthrough, Fast Track, and Orphan designations. The all-stock Werewolf-Ambros merger and oversubscribed $150 million private placement fund development through topline in 2028.
Full story: https://getbiobrief.com/story/neridronate-phase3-150m-merger-financing

### CRPS-1 Patients Gain Hope as $150M Merger Advances Neridronate
2026-08-22 01:34:27 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The Werewolf-Ambros merger creates a Nasdaq-listed company focused on neridronate for CRPS-1, an under-served pain indication affecting 65,000 newly diagnosed U.S. patients yearly. A $150 million financing funds a 270-patient pivotal Phase 3 trial with topline data expected in 2028.
Full story: https://gethealthbrief.com/story/crps1-patients-150m-merger-neridronate

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.